1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68(6):394–424.
2.Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH: Therapeutic developments in pancreatic cancer: current and future perspectives. Nature reviews Gastroenterology & hepatology 2018, 15(6):333–348.
3.Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2007, 25(15):1960–1966.
4.Cao J, Chen X, Ying M, He Q, Yang B: DJ–1 as a Therapeutic Target Against Cancer. Advances in experimental medicine and biology 2017, 1037:203–222.
5.Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H: DJ–1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochemical and biophysical research communications 1997, 231(2):509–513.
6.He X, Zheng Z, Li J, Ben Q, Liu J, Zhang J, Ji J, Yu B, Chen X, Su L et al: DJ–1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis 2012, 33(3):555–562.
7.Takahashi-Niki K, Kato-Ose I, Murata H, Maita H, Iguchi-Ariga SM, Ariga H: Epidermal Growth Factor-dependent Activation of the Extracellular Signal-regulated Kinase Pathway by DJ–1 Protein through Its Direct Binding to c-Raf Protein. The Journal of biological chemistry 2015, 290(29):17838–17847.
8.Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T et al: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 2009, 136(1):206–216.
9.Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H: Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research 2011, 17(9):2744–2756.
10.Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC: Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Neoplasia 2016, 18(7):425–435.
11.Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M et al: Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International journal of oncology 2017, 50(6):2049–2058.
12.Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC: Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2014, 20(15):4047–4058.
13.Park SJ, Kim SM, Moon JH, Kim JH, Shin JS, Hong SW, Shin YJ, Lee DH, Lee EY, Hwang IY et al: SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2016, 37(4):4323–4330.
14.Du J, He Y, Wu W, Li P, Chen Y, Hu Z, Han Y: Targeting EphA2 with miR–124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. The Journal of pharmacy and pharmacology 2019, 71(2):196–205.
15.Choi M, Bien H, Mofunanya A, Powers S: Challenges in Ras therapeutics in pancreatic cancer. Seminars in cancer biology 2019, 54:101–108.
16.Liu D, Yang C, Bojdani E, Murugan AK, Xing M: Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. Journal of the National Cancer Institute 2013, 105(21):1617–1627.
17.Seto M, Ohta M, Ikenoue T, Sugimoto T, Asaoka Y, Tada M, Mohri D, Kudo Y, Ijichi H, Tateishi K et al: Reduced expression of RAS protein activator like–1 in gastric cancer. Int J Cancer 2011, 128(6):1293–1302.
18.Zhu J, Jiang Z, Gao F, Hu X, Zhou L, Chen J, Luo H, Sun J, Wu S, Han Y et al: A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer. PloS one 2011, 6(11):e28223.